Phase 3 Trial Results Show Promise for Drug to Treat Severe Hypoglycemia

May 5, 2021

Earlier this week Diabetes Care published results from a Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. Zealand Pharma is marketing the drug as Zegalogue. The study found that dasiglucagon administration resulted in a reversal of hypoglycemia (with a median recovery time of 10 minutes) with 99% of […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

←My Accidental Path Into Research and Thoughts on Grooming the Next Generation of Physician-Scientists

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today